OncoGenex Pharmaceuticals Inc (OGXI)

2.04
0.01 0.44
NASDAQ : Health Care
Prev Close 2.03
Open 2.12
Day Low/High 2.03 / 2.16
52 Wk Low/High 2.03 / 10.18
Volume 60.16K
Avg Volume 31.50K
Exchange NASDAQ
Shares Outstanding 2.74M
Market Cap 11.66M
EPS -7.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

4 Stocks Under $10 to Trade for Big Breakouts

4 Stocks Under $10 to Trade for Big Breakouts

These stocks trading for less than $10 a share are within range of triggering major breakout trades.

OncoGenex Pharmaceuticals (OGXI) Is Today's Strong On High Volume Stock

OncoGenex Pharmaceuticals (OGXI) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified OncoGenex Pharmaceuticals (OGXI) as a strong on high relative volume candidate

OncoGenex Pharmaceuticals (OGXI) Weak On High Volume Today

OncoGenex Pharmaceuticals (OGXI) Weak On High Volume Today

Trade-Ideas LLC identified OncoGenex Pharmaceuticals (OGXI) as a weak on high relative volume candidate

Revisiting 2 Little Biotech Gems

They both have even more upside momentum. 

Small-Cap Friday's Little Gem

One small pharmaceutical company has big potential.

5 Stocks Poised for Breakouts: Trulia and More

5 Stocks Poised for Breakouts: Trulia and More

These are the stocks that often go on to make monster moves to the upside.

Some of Soros' Stocks Surged Today, While Others Soured

Some of Soros' Stocks Surged Today, While Others Soured

OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), MCG Capital Corp (NASDAQ:MCGC) and Doral Financial Corp. (NYSE:DRL) made noteworthy gains on the market this Wednesday. In the red today are Cal Dive In...

5 Stocks Under $10 to Trade for Breakouts

5 Stocks Under $10 to Trade for Breakouts

These under-$10 stocks are within range of triggering breakout trades.

4 Under-$10 Biotech Stocks in Breakout Territory

4 Under-$10 Biotech Stocks in Breakout Territory

These biotech stocks trading for less than $10 a share are within range of triggering breakout trades.

4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure

The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure

The F-R Rule is still 100% accurate predicting failure for oncology phase III studies undertaken by companies with market caps less than $300 million.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

Why OncoGenex (OXGI) Stock Hit a One-Year Low Today

Why OncoGenex (OXGI) Stock Hit a One-Year Low Today

OncoGenex (OXGI) plummeted to a one-year low after the company announced its experimental prostate cancer treatment failed to show any statistically significant improvements in a late-stage trial.

3 Big-Volume Stocks in Breakout Territory

3 Big-Volume Stocks in Breakout Territory

These stocks trading on unusual volume are within range of triggering breakout trades.

Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!

Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Biotech Stock Mailbag: Vanda, Onconova, Catalyst Pharma, Sarepta

Biotech Stock Mailbag: Vanda, Onconova, Catalyst Pharma, Sarepta

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Oversold Conditions For OncoGenex Pharmaceuticals (OGXI)

Oversold Conditions For OncoGenex Pharmaceuticals (OGXI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

OncoGenex Pharmaceuticals Getting Very Oversold (OGXI)

OncoGenex Pharmaceuticals Getting Very Oversold (OGXI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Purchase OncoGenex Pharmaceuticals At $7.50, Earn 14.9% Annualized

Commit To Purchase OncoGenex Pharmaceuticals At $7.50, Earn 14.9% Annualized

Investors considering a purchase of OncoGenex Pharmaceuticals, Inc. shares, but cautious about paying the going market price of $9.18/share, might benefit from considering selling puts among the alternative strategies at their disposal.

OncoGenex Pharmaceuticals Becomes Oversold (OGXI)

OncoGenex Pharmaceuticals Becomes Oversold (OGXI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

OncoGenex Stock Gaps Down On Today's Open (OGXI)

OncoGenex Stock Gaps Down On Today's Open (OGXI)

Shares of OncoGenex Pharmaceuticals (Nasdaq:OGXI) were gapping down Friday morning with an open price 19.7% lower than Thursday's closing price. The stock closed at $17.43 yesterday and opened today's trading at $13.99.

Teva And OncoGenex Announce Updates To Custirsen Development Program In Advanced Prostate Cancer

Teva And OncoGenex Announce Updates To Custirsen Development Program In Advanced Prostate Cancer

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) and OncoGenex Pharmaceuticals, Inc.

Edison Expands Oncology Sector Presence With Launch Of Research Coverage On OncoGenex Pharmaceuticals

Edison Investment Research, a UK-based independent equity research firm, announces the initiation of research coverage on OncoGenex Pharmaceuticals (NASDAQ:OGXI), a US/Canadian drug discovery and development company.

10 Health-Care Stocks Outperforming the Index

These health-care stocks delivered attractive returns in the past one month, outperforming the index.

Teva And OncoGenex To Present Data On Custirsen In Prostate Cancer At The 2011 ASCO Annual Meeting

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) and OncoGenex Pharmaceuticals, Inc.

9 Health Care Stocks With 100% Buy Ratings

Analysts expect these stocks to outperform their peers and broader markets.